Knop, Filip K.

Effects of lixisenatide on elevated liver transaminases: Systematic review with individual patient data meta-analysis of randomised controlled trials on patients with type 2 diabetes

Gluud, L. L., Knop, F. K., & Vilsbøll, T. (2014) · BMJ Open

Diabetes Treatment and ManagementLiver Disease Diagnosis and Treatment

Cited by 59

Four weeks of near‐normalization of blood glucose has no effect on postprandial GLP‐1 and GIP secretion, but augments pancreatic B‐cell responsiveness to a meal in patients with Type 2 diabetes

Højberg, P. V., Vilsbøll, T., Zander, M., Knop, F. K., Krarup, T., Vølund, A., Holst, J. J., & Madsbad, S. (2008) · Diabetic Medicine

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 56

New Avenues in the Regulation of Gallbladder Motility—Implications for the Use of Glucagon-Like Peptide–Derived Drugs

Gether, I. M., Nexøe-Larsen, C., & Knop, F. K. (2019) · The Journal of Clinical Endocrinology & Metabolism

Gallbladder and Bile Duct DisordersDiabetes Treatment and Management

Cited by 56

Effects of liraglutide on gallbladder emptying: A randomized, placebo‐controlled trial in adults with overweight or obesity

Nexøe‐Larsen, C. C., Sørensen, P. H., Hausner, H., Agersnap, M., Baekdal, M., Brønden, A., Gustafsson, L. N., Sonne, D. P., Vedtofte, L., Vilsbøll, T., et al. (2018) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementGallbladder and Bile Duct Disorders

Cited by 51

Efficacy and safety of glimepiride with or without linagliptin treatment in patients with HNF1A diabetes (maturity-onset diabetes of the young type 3): a randomized, double-blinded, placebo-controlled, crossover trial (GLIMLINA)

Christensen, A. S., Hædersdal, S., Støy, J., Storgaard, H., Kampmann, U., Forman, J. L., Seghieri, M., Holst, J. J., Hansen, T., Knop, F. K., et al. (2020) · Diabetes Care

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 48

Current evidence for a role of GLP-1 in Roux-en-Y gastric bypass-induced remission of type 2 diabetes

Rhee, N. A., Vilsbøll, T., & Knop, F. K. (2012) · Diabetes, Obesity and Metabolism

Bariatric Surgery and OutcomesDiabetes Treatment and Management

Cited by 47

EJE PRIZE 2018: A gut feeling about glucagon

Knop, F. K. (2018) · European Journal of Endocrinology

Pancreatic function and diabetesDiabetes Treatment and Management

Cited by 47

Effect of oral semaglutide on energy intake, appetite, control of eating and gastric emptying in adults living with obesity: A randomized controlled trial

Gabe, M. B. N., Breitschaft, A., Knop, F. K., Hansen, M. R., Kirkeby, K., Rathor, N., & Adrian, C. L. (2024) · Diabetes, Obesity and Metabolism

Pharmacology and Obesity TreatmentRegulation of Appetite and Obesity

Cited by 46

A long‐acting glucose‐dependent insulinotropic polypeptide receptor agonist improves the gastrointestinal tolerability of glucagon‐like peptide‐1 receptor agonist therapy

Knop, F. K., Urva, S., Rettiganti, M., Benson, C. T., Roell, W. C., Mather, K. J., Haupt, A., & Pratt, E. J. (2024) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 41

The role of GLP-1 in the postprandial effects of acarbose in type 2 diabetes

Dalsgaard, N. B., Gasbjerg, L. S., Hansen, L. S., Hansen, N. L., Stensen, S., Hartmann, B., Rehfeld, J. F., Holst, J. J., Vilsbøll, T., & Knop, F. K. (2021) · European Journal of Endocrinology

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 37

GIP’s involvement in the pathophysiology of type 2 diabetes

Christensen, M. B., Gasbjerg, L. S., Heimbürger, S. M., Stensen, S., Vilsbøll, T., & Knop, F. K. (2020) · Peptides

Pancreatic function and diabetesDiabetes Treatment and Management

Cited by 35

Involvement of steatosis-induced glucagon resistance in hyperglucagonaemia

Suppli, M. P., Lund, A., Bagger, J. I., Vilsbøll, T., & Knop, F. K. (2016) · Medical Hypotheses

Pancreatic function and diabetesDiabetes Treatment and Management

Cited by 35

Erratum: Effect of GLP ‐1 receptor agonist treatment on body weight in obese antipsychotic‐treated patients with schizophrenia: A randomized, placebo‐controlled trial

Ebdrup, B. H., Broberg, B. V., Ishøy, P. L., Bak, N., Andersen, U. B., Jørgensen, N. R., Holst, J. J., Knop, F. K., & Glenthøj, B. Y. (2018) · Diabetes, Obesity and Metabolism

Pharmacology and Obesity TreatmentSchizophrenia research and treatment

Cited by 35

Glucagon-like peptide-1 analogs against antipsychotic-induced weight gain: potential physiological benefits

Ebdrup, B. H., Knop, F. K., Ishøy, P. L., Rostrup, E., Fagerlund, B., Lublin, H., & Glenthøj, B. (2012) · BMC Medicine

Schizophrenia research and treatmentPharmacology and Obesity Treatment

Cited by 34

The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus

Christensen, M., Miossec, P., Larsen, B. D., Werner, U., & Knop, F. K. (2014) · Expert Opinion on Drug Discovery

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 34

Adverse drug reactions associated with the use of liraglutide in patients with type 2 diabetes – focus on pancreatitis and pancreas cancer

Chalmer, T., Almdal, T. P., Vilsbøll, T., & Knop, F. K. (2015) · Expert Opinion on Drug Safety

Diabetes Treatment and ManagementPancreatic and Hepatic Oncology Research

Cited by 31

56-OR: A Long-Acting Glucose-Dependent Insulinotropic Polypeptide Receptor Agonist Shows Weight Loss without Nausea or Vomiting

KNOP, F. K., URVA, S., RETTIGANTI, M., BENSON, C., ROELL, W., MATHER, K. J., HAUPT, A., & PRATT, E. J. (2023) · Diabetes

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 29

Glucagonostatic potency of GLP-1 in patients with type 2 diabetes, patients with type 1 diabetes, and healthy control subjects

Bagger, J. I., Grøndahl, M. F. G., Lund, A., Holst, J. J., Vilsbøll, T., & Knop, F. K. (2021) · Diabetes

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 27

Bone Status in Obese, Non-diabetic, Antipsychotic-Treated Patients, and Effects of the Glucagon-Like Peptide-1 Receptor Agonist Exenatide on Bone Turnover Markers and Bone Mineral Density

Eriksson, R., Broberg, B. V., Ishøy, P. L., Bak, N., Andersen, U. B., Jørgensen, N. R., Knop, F. K., & Ebdrup, B. H. (2019) · Frontiers in Psychiatry

Bone health and osteoporosis researchSchizophrenia research and treatment

Cited by 26

Evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating the neuroprotective effects of semaglutide in early Alzheimer’s disease.

Atri, A., Feldman, H. H., Hansen, C. T., Honore, J. B., Johannsen, P., Knop, F. K., Poulsen, P., Raket, L. L., Sano, M., Soininen, H., et al. (2022) · Alzheimer's & Dementia

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 24

Once‐weekly subcutaneous semaglutide treatment for persons with type 2 diabetes: Real‐world data from a diabetes out‐patient clinic

Hansen, K. B., Svendstrup, M., Lund, A., Knop, F. K., Vilsbøll, T., & Vestergaard, H. (2021) · Diabetic Medicine

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 23

Cardiovascular biomarkers in clinical studies of type 2 diabetes

Baldassarre, M. P. A., Andersen, A., Consoli, A., Knop, F. K., & Vilsbøll, T. (2018) · Diabetes, Obesity and Metabolism

Diabetes, Cardiovascular Risks, and LipoproteinsDiabetes Treatment and Management

Cited by 22

Glucose‐dependent insulinotropic polypeptide induces lipolysis during stable basal insulin substitution and hyperglycaemia in men with type 1 diabetes: A randomized, double‐blind, placebo‐controlled, crossover clinical trial

Heimburger, S. M. N., Nielsen, C. N., Calanna, S., Holst, J. J., Vilsbøll, T., Knop, F. K., & Christensen, M. B. (2022) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 13

Higher endogenous glucose production during OGTT vs isoglycemic intravenous glucose infusion

Lund, A., Bagger, J. I., Christensen, M., Grøndahl, M., van Hall, G., Holst, J. J., Vilsbøll, T., & Knop, F. K. (2016) · The Journal of Clinical Endocrinology & Metabolism

Pancreatic function and diabetesDiabetes Treatment and Management

Cited by 12